Uses of monoclonal antibody 8H9
View Patent ↗This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative.
1. A method of inhibiting the growth of tumor cells comprising contacting said tumor cells with a polypeptide comprising a single chain variable fragment (scFv) of monoclonal antibody 8H9, wherein the scFv comprises the amino acid sequence of SEQ ID NO. 40.
2. The method of claim 1 , wherein the 8H9 antibody comprises heavy chain complementary determining region (CDR) sequences comprising NYDIN (SEQ ID NO. 29) for CDR1, WIFPGDGSTQY (SEQ ID NO. 30) for CDR2, and QTTATWFAY (SEQ ID NO. 31) for CDR3.
3. The method of claim 1 , wherein the 8H9 antibody comprises light chain complementary determining region (CDR) sequences comprising PASQSTSDYLH (SEQ ID NO. 32) for CDR1, YASQSIS (SEQ ID NO. 33) for CDR2, and QNGHSFPLT (SEQ ID NO. 34) for CDR3.
4. The method of claim 1 , wherein the 8H9 antibody comprises (i) heavy chain complementary determining region (CDR) sequences comprising NYDIN (SEQ ID NO. 29) for CDR1, WTFPGDGSTQY (SEQ ID NO. 30) for CDR2, and QTTATWFAY (SEQ ID NO. 31) for CDR3, and (ii) light chain CDR sequences comprising RASQSISDYLH (SEQ ID NO. 32) for CDR1, YASQSIS (SEQ ID NO. 33) for CDR2, and QNGHSFPLT (SEQ ID NO. 34) for CDR3.
5. The method of claim 1 , wherein the polypeptide is a scFv fusion construct.
6. The method of claim 5 , wherein the polypeptide is a scFv-Fc fusion construct.
7. The method of claim 5 , wherein the polypeptide comprises sequences of human origin.
8. The method of claim 7 , wherein the sequences of human origin comprise human immunoglobulin sequences.
9. The method of claim 8 , wherein the human immunoglobulin sequences comprise human immunoglobulin constant region sequences.
10. A method of inhibiting the growth of tumor cells in a subject comprising administering to the subject a polypeptide comprising a single chain variable fragment (scFv) derived from monoclonal antibody 8H9, wherein the scFv comprises the amino acid sequence of SEQ ID NO.40.
11. The method of claim 10 , wherein the 8H9 antibody comprises heavy chain complementary determining region (CDR) sequences comprising NYDIN (SEQ ID NO. 29) for CDR1, WIFPGDGSTQY (SEQ ID NO. 30) for CDR2, and QTTATWFAY (SEQ ID NO. 31) for CDR3.
12. The method of claim 10 , wherein the 8H9 antibody comprises light chain complementary determining region (CDR) sequences comprising RASQSISDYLH (SEQ ID NO. 32) for CDR1, YASQSIS (SEQ ID NO. 33) for CDR2, and QNGHSFPLT (SEQ ID NO. 34) for CDR3.
13. The method of claim 10 , wherein the 8H9 antibody comprises (i) heavy chain complementary determining region (CDR) sequences comprising NYDIN (SEQ ID NO. 29) for CDR1, WIFPGDGSTQY (SEQ ID NO. 30) for CDR2, and QTTATWFAY (SEQ ID NO. 31) for CDR3, and (ii) light chain CDR sequences comprising RASQSISDYLH (SEQ ID NO. 32) for CDR1, YASQSIS (SEQ ID NO. 33) for CDR2, and QNGHSFPLT (SEQ ID NO. 34) for CDR3.
14. The method of claim 10 , wherein the polypeptide is a scFv fusion construct.
15. The method of claim 14 , wherein the polypeptide is a scFv-Fc fusion construct.
16. The method of claim 14 , wherein the polypeptide comprises sequences of human origin.
17. The method of claim 16 , wherein the sequences of human origin comprise human immunoglobulin sequences.
18. The method of claim 17 , wherein the human immunoglobulin sequences comprise human immunoglobulin constant region sequences.